MicroRNA-711 is a prognostic factor for poor overall survival and has an oncogenic role in breast cancer

Oncology Letters

Volumn 11, Issue 3, 2016, Pages 2155-2163

  Hu, Jing Ye ^a,b   Yi, Wei ^c   Zhang, Mei Yin ^a   Xu, Rui ^a   Zeng, Li Si ^a   Long, Xiao Ran ^a   Zhou, Xiao Min ^a   Zheng, Xiao Feng Steven ^d   Kang, Yibin ^e   Wang, Hui Yun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Guiyan Traditional Medical College   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e PRINCETON UNIVERSITY   (United States)

Author keywords

Breast cancer; Cell proliferation; miR 711; Prognosis; Reverse transcription quantitative PCR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICRORNA; MICRORNA 711; PROGESTERONE RECEPTOR; RNA; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS ASSAY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PROGNOSIS; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; MRNA EXPRESSION ASSAY; MTT ASSAY; OVERALL SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; UPREGULATION;

EID: 84958041428     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4217     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69–90, 2011.
2. Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893–1907, 2010.
3. Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Héry C and Heanue M: Disparities in breast cancer mortality trends between 30 European countries: Retrospective trend analysis of WHO mortality database. BMJ 341: (aug11 1): c3620, 2010.
4. Doll R, Payne P and Waterhouse JAH (eds): Cancer Incidence in Five Continents. Vol 1. Union Internationale Contre le Cancer, Geneva, 1966.
5. Lacroix M: Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 13: 1033–1067, 2006.
6. Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, et al: Role of the multidisciplinary team in breast cancer management: Results from a large international survey involving 39 countries. Ann Oncol 23: 853–859, 2012.
7. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999–3004, 2004.
8. Wu W, Sun M, Zou GM and Chen J: MicroRNA and cancer: Current status and prospective. Int J Cancer 120: 953–960, 2007.
9. Shenouda SK and Alahari SK: MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev 28: 369–378, 2009.
10. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793–1801, 2005.
11. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189–198, 2006.
12. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol 11: 136–146, 2010.
13. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, et al: MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48–57, 2008.
14. Yousef M, Showe L and Showe M: A study of microRNAs in silico and in vivo: Bioinformatics approaches to microRNA discovery and target identification. FEBS J 276: 2150–2156, 2009.
15. Liu CG, Calin GA, Volinia S and Croce CM: MicroRNA expression profiling using microarrays. Nat Protoc 3: 563-578, 2008.
16. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257–2261, 2006.
17. Dvinge H, Git A, Gräf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, et al: The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497: 378–382, 2013.
18. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281–297, 2004.
19. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H and Dahiya R: Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA 103: 17337–17342, 2006.
20. Morris KV, Chan SW, Jacobsen SE and Looney DJ: Small interfering RNA–induced transcriptional gene silencing in human cells. Science 305: 1289–1292, 2004.
21. Cho WC: MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 42: 1273–1281, 2010.
22. Redell JB, Liu Y and Dash PK: Traumatic brain injury alters expression of hippocampal microRNAs: potential regulators of multiple pathophysiological processes. J Neurosci Res 87: 1435–1448, 2009.
23. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE and Galas DJ: Circulating microRNAs, potential biomarkers for drug–induced liver injury. Proc Natl Acad Sci USA 106: 4402–4407, 2009.
24. Zhao N, Yu H, Sun M, Zhang Y, Xu M and Gao W: MiRNA–711–SP1–collagen–I pathway is involved in the anti–fibrotic effect of pioglitazone in myocardial infarction. Sci China Life Sci 56: 431–439, 2013.
25. American Joint Committee on Cancer: Cancer Staging Manual. Greene FL, Page DL, Fleming ID and Fritz AG (eds). 6th edition. Springer Science+Business Media, New York, NY, pp. 221–240, 2002.
26. Körbler T, Grsković M, Dominis M and Antica M: A simple method for RNA isolation from formalin–fixed and paraffin–embedded lymphatic tissues. Exp Mol Pathol 74: 336–340, 2003.
27. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real–time quantitative PCR and the 2(–Delta Delta C(T)) Method. Methods 25: 402–408, 2001.
28. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew–Goodall Y and Goodall GJ: The miR–200 family and miR–205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593–601, 2008.
29. Wu H, Zhu S and Mo YY: Suppression of cell growth and invasion by miR–205 in breast cancer. Cell Res 19: 439–448, 2009.
30. Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH and Elizalde PV: Downregulation of the tumor–suppressor miR–16 via progestin–mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res 14: R77, 2012.
31. Sabirzhanov B, Stoica BA, Zhao Z, Loane DJ, Wu J, Dorsey SG and Faden AI: miR–711 upregulation induces neuronal cell death after traumatic brain injury. Cell Death Differ: Oct 16, 2015 (Epub ahead of print).
32. Ralfkiaer U, Hagedorn PH, Bangsgaard N, Løvendorf MB, Ahler CB, Svensson L, Kopp KL, Vennegaard MT, Lauenborg B, Zibert JR, et al: Diagnostic microRNA profiling in cutaneous T–cell lymphoma (CTCL). Blood 118: 5891–5900, 2011.